Loading...
XSHE300813
Market cap300mUSD
Dec 27, Last price  
18.10CNY
1D
1.80%
1Q
0.28%
IPO
29.55%
Name

Zhejiang Tailin Bioengineering Co Ltd

Chart & Performance

D1W1MN
XSHE:300813 chart
P/E
111.53
P/S
8.13
EPS
0.16
Div Yield, %
1.24%
Shrs. gr., 5y
7.42%
Rev. gr., 5y
11.15%
Revenues
270m
-27.82%
94,463,28559,499,81482,332,546111,760,610142,018,123159,097,741180,928,327200,237,532283,248,491373,878,114269,856,059
Net income
20m
-75.32%
21,456,57110,122,08915,372,39329,016,35944,987,87948,214,58934,406,39148,385,61363,529,85179,686,20219,668,950
CFO
2m
-97.84%
11,512,35917,508,48524,540,41831,563,27023,043,84637,326,17329,039,126106,282,84535,961,76989,385,6191,931,884
Dividend
May 27, 20240.1 CNY/sh
Earnings
May 14, 2025

Profile

Zhejiang Tailin BioEngineering Co.,Ltd manufactures microbial test and control equipment, mainly for pharmaceutical and medical sector. The company offers sterility testing equipment, microbiological testing equipment, TOC analyzers, sterile isolation systems, hydrogen peroxide sterilization systems, sterile delivery system, and filters, as well as technical services. Its products are primarily used in bio-pharmaceutical, medical, disease control, food, environmental protection, electronics, and other fields, as well as in bio-security equipment manufacturing industries. The company was formerly known as Hangzhou Tailin Biotechnology Equipment Co., Ltd. and changed its name to Zhejiang Tailin BioEngineering Co.,Ltd in April 2015. Zhejiang Tailin BioEngineering Co.,Ltd was founded in 1993 and is based in Hangzhou, China.
URL
http://www.tailingood.com/
IPO date
Jan 14, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
269,856
-27.82%
373,878
32.00%
283,248
41.46%
Cost of revenue
247,406
295,851
209,531
Unusual Expense (Income)
NOPBT
22,450
78,027
73,717
NOPBT Margin
8.32%
20.87%
26.03%
Operating Taxes
3,531
261
6,114
Tax Rate
15.73%
0.33%
8.29%
NOPAT
18,919
77,766
67,603
Net income
19,669
-75.32%
79,686
25.43%
63,530
31.30%
Dividends
(27,172)
(15,591)
(10,394)
Dividend yield
0.96%
0.39%
0.20%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,532
3,468
Long-term debt
157,589
145,467
7,486
Deferred revenue
(412)
57
Other long-term liabilities
1
412
1
Net debt
(243,393)
(452,209)
(330,258)
Cash flow
Cash from operating activities
1,932
89,386
35,962
CAPEX
(176,242)
Cash from investing activities
(172,344)
Cash from financing activities
(13,583)
183,849
FCF
(160,604)
48,651
18,492
Balance
Cash
396,983
577,154
322,509
Long term investments
4,000
22,054
18,703
Excess cash
387,490
580,514
327,050
Stockholders' equity
456,077
449,745
269,363
Invested Capital
420,339
337,750
228,080
ROIC
4.99%
27.49%
29.94%
ROCE
2.77%
9.90%
14.78%
EV
Common stock shares outstanding
115,700
112,600
108,098
Price
24.52
-31.39%
35.74
-25.66%
48.08
103.58%
Market cap
2,836,957
-29.50%
4,024,153
-22.57%
5,197,000
103.58%
EV
2,595,040
3,571,944
4,866,743
EBITDA
36,858
91,351
81,941
EV/EBITDA
70.41
39.10
59.39
Interest
621
882
132
Interest/NOPBT
2.76%
1.13%
0.18%